Medical Oncology

Pancreatic Cancer

Questions discussed in this category

Would you offer consolidative full dose chemo-RT for local residual pancreatic disease in a patient with stage IV pancreatic adenocarcinoma with excellent response after induction chemotherapy?

Would you ever consider this approach for an initially polymetastatic patient?

2 Answers available

How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?

And if delayed, should chemotherapy be started?

2 Answers available

Should immunotherapy be added to standard of care neoadjuvant chemotherapy in borderline resectable MSI-H adenocarcinoma of pancreas?

Is there data to support this approach?

2 Answers available

How would you approach a locally advanced ampullary carcinoma with BRCA1 mutation whose Whipple showed complete pathologic response after 5 cycles of neoadjuvant mFOLFIRINOX?

Patient refuses further mFOLFIRINOX but may be open to less aggressive regimens. Is there any role for PARP inhibitors?

1 Answer available

Would you favor starting with pembrolizumab or chemotherapy for a metastatic MSI-high pancreatic ductal adenocarcinoma?

Would your recommendation change in a patient having pain from disease and you wanted a quick response?

1 Answer available

What are your top takeaways from ASCO GI 2023?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

8 Answers available

Would you recommend adjuvant chemotherapy for a patient with subcentimeter pancreatic adenocarcinoma incidentally found during a Whipple resection for high risk IPMN?

1 Answer available

What is your preferred first line regimen for a patient with BRCA+ metastatic pancreatic cancer with poor performance status?

2 Answers available

What third line treatment do you consider for a patient with metastatic pancreatic cancer with good functional status and no targetable mutations after progression on FOLFIRINOX and gemcitabine/nab-paclitaxel?

3 Answers available

Papers discussed in this category

N. Engl. J. Med., 2019 Jun 02

Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-20

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Pancreatology, 2020 Oct 18

Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.

Lancet (London, England), 2016-02-06

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

European journal of cancer (Oxford, England : 1990), 2019-02

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007-11

Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer.

Annals of surgery, 2010-03

Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.

Cancer, 2016-02-15

The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).

Cancer, 2019-01-01

Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.

HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017-07

Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?

N. Engl. J. Med.,

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

The New England journal of medicine, 2013-10-31

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Lancet, 2021 Jun 05

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Eur J Cancer, 2018 Aug 24

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

J Clin Oncol, 2019 Nov 04

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Gut, 2020 Apr 29

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.

American journal of clinical oncology, 2023 Dec 22

Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Review and Guidelines.

Int J Radiat Oncol Biol Phys, 2022 Jul 04

A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer.

Lancet (London, England), 2023 Dec 14

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

Medical Oncology

Pancreatic Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology